2016南半球流感季流感疫苗效果随接种时间下降:检测阴性设计及系统发育评估
该研究基于澳大利亚全科诊所三个常规症候群哨点监测系统数据,采用检测阴性设计评估2016南半球流感季灭活流感疫苗效果。共纳入1085例患者,447例(41%)流感阳性,以A/H3N2为主(74%)。总体疫苗效果(VE)为40%(95%CI:18-56%),症状出现前2个月内接种者VE最高(60%,95%CI:26-78%),超过4个月接种者VE最低(19%,95%CI:-73-62%)。
要点
- 2016南半球流感疫苗总体VE为40%(95%CI:18-56%)。
- 症状出现前2个月内接种VE为60%(95%CI:26-78%)。
- 接种超过4个月后VE降至19%(95%CI:-73-62%)。
核心结论
- 2016南半球流感疫苗对实验室确诊流感感染总体提供良好保护,但疫苗效果随接种后时间延长显著下降,临近流感季接种可获得最佳保护。
研究设计与样本
- 采用检测阴性设计,数据来自澳大利亚全科诊所三个常规症候群哨点监测系统,共纳入2016年1085例接受流感检测的患者,并使用下一代测序对病毒进行特征分析。
主要发现
- 1085例患者中447例(41%)流感阳性,其中多数为A/H3N2(74%),31%的患者接种了2016南半球流感疫苗。
- 总体VE为40%(95%CI:18-56%)。
- 症状出现前2个月内接种者VE为60%(95%CI:26-78%),超过4个月接种者VE为19%(95%CI:-73-62%)。
关键数值与推荐
- 总体VE:40%(95%CI:18-56%)。
- 症状出现前2个月内接种VE:60%(95%CI:26-78%)。
- 症状出现前超过4个月接种VE:19%(95%CI:-73-62%)。
临床怎么用
- 建议在流感季临近时接种流感疫苗,以获取最佳保护效果。
- 对较早接种者需关注疫苗效果随时间下降的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We estimated the effectiveness of seasonal inactivated influenza vaccine and the potential influence of timing of immunization on vaccine effectiveness (VE) using data from the 2016 southern hemisphere influenza season. METHODS: Data were pooled from three routine syndromic sentinel surveillance systems in general practices in Australia. Each system routinely collected specimens for influenza testing from patients presenting with influenza-like illness. Next generation sequencing was used to characterize viruses. Using a test-negative design, VE was estimated based on the odds of vaccination among influenza-positive cases as compared to influenza-negative controls. Subgroup analyses were used to estimate VE by type, subtype and lineage, as well as age group and time between vaccination and symptom onset. RESULTS: A total of 1085 patients tested for influenza in 2016 were included in the analysis, of whom 447 (41%) tested positive for influenza. The majority of detections were influenza A/H3N2 (74%). One-third (31%) of patients received the 2016 southern hemisphere formulation influenza vaccine. Overall, VE was estimated at 40% (95% CI: 18-56%). VE estimates were highest for patients immunized within two months prior to symptom onset (VE: 60%; 95% CI: 26-78%) and lowest for patients immunized >4 months prior to symptom onset (VE: 19%; 95% CI: -73-62%). DISCUSSION: Overall, the 2016 influenza vaccine showed good protection against laboratory-confirmed infection among general practice patients. Results by duration of vaccination suggest a significant decline in effectiveness during the 2016 influenza season, indicating immunization close to influenza season offered optimal protection.
引用
- Regan AK, Fielding JE, Chilver MB, et al. Intraseason decline in influenza vaccine effectiveness during the 2016 southern hemisphere influenza season: A test-negative design study and phylogenetic assessment. Vaccine. 2019. PMID: 30952499. doi:10.1016/j.vaccine.2019.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。